证券代码：300705 证券简称：九典制药 债券代码：123110 债券简称：九典转债 湖南九典制药股份有限公司 投资者关系活动记录表 编号：2022-21 | --- | --- | --- | --- | --- | --- | --- | |-----------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-------|-------|----------------|-------| | 投资者关系活动 \n类别 | □特定对象调研 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n□现场参观 | □分析师会议 \n 其他 线上调研 | | | | | | 参与单位名称及 | 金世富盈、环球时刻（北京）、国盛证券 | 6 | | | 位机构投资者代 ...

证券代码：300705 证券简称：九典制药 债券代码：123110 债券简称：九典转债 编号：2022-27 | --- | --- | --- | --- | --- | |-----------------------|-----------------------------------------|------------------------------------------------------|--------------------|------------| | 投资者关系活动 | □特定对象调研 \n□媒体采访 □业绩说明会 | □分析师会议 | | | | 类别 | □新闻发布会 □路演活动 | | | | | | □现场参观 | 其他 2022 | 年第三季度业绩说明 | | | 参与单位名称及 | 电话会议 | 德邦证券、平安证券、首创证券、申万宏源、方正证券、安 | | | | 人员姓名 | 证券等 88 位机构及个人投资者 | 信基金、华夏基金、国泰基金、玖歌投资、彤源投资、招商 | | | | 时间 2022 | 年 10 月 28 日下午 | 15:00-15:40 | ...

Financial Performance - The company's revenue for Q3 2022 reached ¥568,212,860.39, representing a 42.82% increase compared to the same period last year[5] - Net profit attributable to shareholders was ¥78,622,110.11, up 39.41% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥77,176,911.73, reflecting a 46.25% increase from the previous year[5] - The company reported a total of ¥90,259,643.84 in trading financial assets, down from ¥100,314,246.58[18] - The net profit for the third quarter was 208,389,289.18, an increase of 23.1% compared to 169,211,746.27 in the same period last year[32] - Operating profit reached 231,054,782.41, up from 187,884,885.27, reflecting a growth of 22.9% year-over-year[32] - Total revenue from operating activities was 1,740,154,700.95, compared to 1,268,663,192.10, marking a year-over-year increase of 37.1%[33] - The total profit for the period was 230,472,568.29, compared to 187,535,180.75, showing an increase of 22.9% year-over-year[32] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥2,038,665,448.50, a 16.81% increase from the end of the previous year[5] - The company's total liabilities reached CNY 774,739,577.46, compared to CNY 645,899,203.77, marking an increase of 19.9%[25] - Non-current liabilities rose to CNY 414,086,794.87, up from CNY 275,523,196.97, indicating a 50.4% increase[25] - The equity attributable to shareholders increased to CNY 1,263,925,871.04 from CNY 1,099,337,578.54, a growth of 15%[25] Cash Flow - Cash flow from operating activities for the year-to-date was ¥166,513,197.28, showing a significant increase of 73.87%[10] - Cash flow from operating activities generated a net amount of 166,513,197.28, compared to 95,766,161.00 in the previous year, indicating a significant improvement[36] - Investment activities resulted in a net cash outflow of -285,124,174.85, compared to -242,069,533.61 in the same period last year[36] Shareholder Information - The top shareholder, Zhu Zhihong, holds 35.75% of shares, totaling 117,474,000 shares[14] - The second-largest shareholder, Duan Lixin, owns 14.78% of shares, amounting to 48,561,005 shares[14] - The company has a total of 10,086 common stock shareholders at the end of the reporting period[14] Research and Development - The company's R&D expenses for the period were ¥128,529,979.49, which is a 41.70% increase due to new R&D projects[10] - Research and development expenses were CNY 128,529,979.49, representing a 41.7% increase from CNY 90,708,588.17 year-over-year[26] Current Assets - Total current assets as of September 30, 2022, amounted to ¥1,070,000,000, a decrease from ¥1,200,000,000 at the beginning of the year[18] - Cash and cash equivalents decreased to ¥322,894,203.81 from ¥398,405,362.65, reflecting a decline of approximately 19%[18] - Accounts receivable increased significantly to ¥370,068,745.49 from ¥248,853,047.33, representing a growth of about 48.5%[18] - Inventory rose to ¥264,520,420.81, up from ¥214,478,519.60, indicating an increase of approximately 23.3%[18] - Other receivables increased to ¥3,151,993.75 from ¥2,150,570.41, marking a rise of approximately 46.5%[18] Operating Costs - Total operating costs amounted to CNY 1,367,842,381.56, up 43.8% from CNY 951,368,579.56 in the prior period[26] - The company reported a significant increase in sales expenses, which totaled CNY 817,858,940.49, up from CNY 567,383,854.88, reflecting a 44.0% rise[26] Credit Impairment - The company experienced a 73.03% increase in credit impairment losses, primarily due to an increase in accounts receivable[10] - The company incurred credit impairment losses of -7,036,771.77, which increased from -4,066,792.83 in the previous year[32]

证券代码：300705 证券简称：九典制药 公告编号：2022-068 债券代码：123110 债券简称：九典转债 湖南九典制药股份有限公司 关于参加湖南辖区上市公司 2022 年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流,使广大投资者能更深入全面了解公司情 况，湖南九典制药股份有限公司（以下简称"公司"）将参加由中国证券监督管 理委员会湖南监管局、湖南省上市公司协会与深圳市全景网络有限公司联合举办 的"湖南辖区上市公司 2022 年投资者网上集体接待日活动"，现将相关事项公 告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台采取网络远程的方式举行，投资者可以登录"全景路演"网站 （http://rs.p5w.net/）参与本次活动，活动时间为 2022 年 9 月 29 日（星期四） 15:30-16:55。 届时公司副总经理兼董事会秘书曾蕾女士及证券事务代表甘荣女士将通过 网络在线问答互动的形式，与投资者进行沟通和交流。 欢迎广大投资者积极参与！ 特此公告。 ...

Financial Performance - The company reported a total revenue of 300 million RMB for the first half of 2022, representing a year-on-year increase of 15%[20]. - The net profit attributable to shareholders was 50 million RMB, an increase of 20% compared to the same period last year[20]. - The company's operating revenue for the reporting period reached ¥1,030,962,019.57, representing a 40.89% increase compared to ¥731,736,212.50 in the same period last year[29]. - Net profit attributable to shareholders was ¥129,767,179.07, up 15.02% from ¥112,816,707.60 year-on-year[29]. - The net profit after deducting non-recurring gains and losses was ¥124,361,287.81, reflecting a 22.11% increase from ¥101,840,900.89 in the previous year[29]. - Future guidance estimates a revenue growth of 20% for the full year 2022, driven by new product launches and market expansion efforts[20]. - The sales revenue from the company's main product, the transdermal patch of Loxoprofen Sodium, reached CNY 575.72 million, with a year-on-year growth of 57.90%[52]. - The revenue from the raw materials and pharmaceutical excipients business was CNY 185.45 million, showing a significant increase of 72.66%[53]. - The sales revenue of the company's raw materials reached CNY 59.66 million, reflecting a year-on-year growth of 65.58%[56]. - The sales revenue from pharmaceutical formulations was CNY 847.54 million, which is a 38.88% increase year-on-year[52]. Research and Development - The company plans to invest 10 million RMB in R&D for new drug development in the upcoming year[20]. - The company has a strong commitment to R&D and process optimization, creating high product barriers and ensuring clinical advantages for its products[45]. - The company has established a strong R&D model focusing on independent development, with ongoing optimization of existing production processes[63]. - The company has a research and development team of 450 people, primarily composed of PhDs, Masters, and overseas returnees, focusing on transdermal drug delivery systems[79]. - The company has nearly 100 products under research and application, significantly enriching its product pipeline, particularly in the fields of anti-inflammatory analgesics, digestive systems, cardiovascular, anti-allergy, and calming supplements[100]. - The company has developed 61 new raw material drug varieties, ensuring a wide range of products and series, with a high domestic market share for erythromycin and levofloxacin[101]. - The company has established various innovation platforms, including a postdoctoral research station and engineering research centers for respiratory drugs and new gel formulations[79]. - The company has submitted production applications for 11 new products, currently under CDE review, including Ketoprofen plaster and Aluminum magnesium chewable tablets[64]. Market Expansion and Strategy - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 30% increase in market share by 2023[20]. - The company is focusing on expanding its market presence through active participation in national and local centralized drug procurement initiatives[52]. - The company is adapting to industry changes, with a focus on innovative drugs gaining competitive advantages amid increasing domestic pharmaceutical competition[51]. - The company is actively pursuing market expansion through direct sales and partnerships with qualified pharmaceutical distributors[62]. - The company is enhancing its accounts receivable management to mitigate risks associated with overdue payments and bad debts, which could adversely affect its profitability[144]. Intellectual Property and Compliance - The company and its subsidiaries hold a total of 108 patents, including 36 invention patents, 8 utility model patents, and 64 design patents as of the end of the reporting period[81]. - The company is focused on expanding its intellectual property portfolio to enhance its competitive edge in the pharmaceutical market[81]. - The company has implemented measures to ensure that all pollutants are treated before discharge, achieving compliance with environmental standards[168]. - The company has a complete quality assurance system, ensuring compliance with GMP requirements throughout the entire production process[103]. - The company is subject to strict regulatory requirements for drug production licenses and must renew these certifications before expiration to avoid significant operational impacts[142]. Environmental Compliance - The company reported a chemical oxygen demand (COD) emission of 1.3 tons, which is within the standard limit of COD ≤ 29 tons[165]. - The ammonia nitrogen (NH3-N) emission was recorded at 4.92 tons per annum, compliant with the standard limit of NH3-N ≤ 0.79 tons per annum[165]. - The company has successfully maintained all emissions within the regulatory limits, with no exceedances reported[168]. - The company has a solid waste management system in place, ensuring hazardous waste is handled according to regulations and transferred to qualified disposal companies[178]. - The company has conducted emergency drills for environmental risk management, with the latest drill held in June 2022[185]. Shareholder Engagement - The company held multiple investor communication sessions with participation from 71 institutional and individual investors on March 8, 2022, discussing operational conditions and stock incentive plans[153]. - The company approved a restricted stock incentive plan on March 28, 2022, granting a total of 5.3 million shares at a price of 13.94 CNY per share to 72 incentive recipients[161]. - The company did not distribute cash dividends or bonus shares for the first half of 2022[157]. - The company’s investor relations activities included discussions on governance and industry conditions, reflecting a proactive approach to stakeholder engagement[154].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 234.69 million RMB, marking a year-on-year growth of 15%[10]. - The company's operating revenue for 2021 was CNY 1,627,664,942.20, representing a 66.40% increase compared to CNY 978,159,132.00 in 2020[35]. - The net profit attributable to shareholders for 2021 was CNY 204,245,777.25, a significant increase of 148.29% from CNY 82,259,768.22 in 2020[35]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 180,130,249.20, up 167.87% from CNY 67,246,404.11 in the previous year[35]. - The basic earnings per share for 2021 was CNY 0.87, which is a 148.57% increase from CNY 0.35 in 2020[35]. - The total assets at the end of 2021 amounted to CNY 1,745,236,782.31, reflecting a 54.35% increase from CNY 1,130,719,874.02 at the end of 2020[35]. - The net assets attributable to shareholders at the end of 2021 were CNY 1,099,337,578.54, a 31.55% increase from CNY 835,682,214.34 at the end of 2020[35]. - The weighted average return on net assets for 2021 was 20.88%, up from 10.31% in 2020, indicating improved profitability[35]. - The company reported a comprehensive diluted earnings per share of CNY 0.8703 for the latest share capital[38]. - The company's total revenue for Q1, Q2, Q3, and Q4 was approximately ¥278.11 million, ¥453.63 million, ¥397.86 million, and ¥498.06 million respectively, showing a strong performance throughout the year[39]. - The net profit attributable to shareholders for the same quarters was ¥46.45 million, ¥66.37 million, ¥56.40 million, and ¥35.03 million, indicating fluctuations in profitability[39]. - The net cash flow from operating activities for 2021 was CNY 190,871,610.34, an increase of 27.25% compared to CNY 149,994,591.77 in 2020[35]. Research and Development - The company is focusing on enhancing its research and development capabilities as a core competitive advantage, despite facing potential risks in product and technology development[7]. - The company has developed a high drug-loading transdermal patch system for Loxoprofen Sodium Gel, which is the only medical insurance formulation for treating musculoskeletal diseases, ensuring a significant clinical advantage and broad market prospects[57]. - The company has established a technology innovation mechanism that relies on research institutions to jointly conduct project research and development[75]. - The company has a research and development team of 460 members, primarily composed of PhDs, Masters, and overseas returnees, emphasizing its commitment to innovation[93]. - The company has 12 products in the clinical trial phase, including PDX-02 for inflammation and pain, which was approved for clinical trials in January 2022[79]. - The company has made progress in the development of new technologies and formulations to enhance drug efficacy[83]. - The company is focusing on the development of new products and technologies to enhance its market position[188]. Market Strategy and Sales - The company plans to maintain a high level of sales expenses in the short term due to business expansion and new product launches, which may affect profitability if sales growth does not keep pace[12]. - The company has adjusted its sales model to increase the proportion of cooperative distribution, which is expected to enhance market penetration[9]. - The company is expanding its market presence through strategic partnerships and exploring new sales models, including direct sales and e-commerce[122]. - The company primarily utilizes a "cooperative distribution" sales model for its pharmaceutical formulations, selecting high-quality pharmaceutical companies as distributors[74]. - The company is actively pursuing acquisitions of competitive products with good market prospects to enhance its product portfolio[75]. Regulatory and Compliance - The company is subject to regulatory risks related to the renewal of necessary production licenses, which could impact its ability to operate legally if not managed properly[8]. - The company has faced environmental compliance challenges in the past, which could lead to increased operational costs if stricter regulations are imposed[14]. - The company is committed to maintaining compliance with regulatory standards, ensuring the quality and safety of its products[83]. - The company emphasized its commitment to improving corporate governance and internal control systems, aligning with regulatory requirements from the China Securities Regulatory Commission and the Shenzhen Stock Exchange[200]. Financial Management - The company has implemented measures to strengthen accounts receivable management to mitigate the risk of bad debts, which have increased alongside business growth[12]. - The company completed the issuance of convertible bonds, raising 270 million yuan to support operational funding[131]. - The company has invested 100 million yuan in structured deposit financial products, with remaining funds allocated for planned investment in fundraising projects[172]. - The company aims to enhance capital performance management by optimizing asset structure and reducing accounts receivable ratio[186]. Product Development and Innovation - The company has successfully registered 5 new drug certificates in 2021 and completed 3 consistency evaluations for generic drugs, indicating a strong pipeline and regulatory compliance[58]. - The company has developed over 40 new raw material drug varieties, enhancing its product diversity and series completeness[110]. - The company has launched new products including 5 drugs that are covered by national medical insurance, enhancing its market presence[83]. - The company has established various innovation platforms, including a post-doctoral research workstation and several engineering research centers[93]. - The company is focusing on expanding its product offerings in the cardiovascular and anti-thrombotic segments[83]. Corporate Governance and Investor Relations - The company held multiple investor communication sessions throughout 2021, including quarterly earnings calls and annual reports, with participation from various institutional investors[193][196]. - The company maintained a proactive approach in its investor relations, ensuring regular updates and engagement with stakeholders throughout the year[193]. - The company engaged with a diverse range of institutional investors, including major securities and asset management firms, to discuss its performance and industry trends[193][196]. - The company reported on its production and operational status during investor meetings, indicating a focus on transparency and stakeholder engagement[193][196].

Financial Performance - The company's revenue for Q1 2022 was CNY 449,062,914.36, representing a 61.47% increase compared to CNY 278,106,139.44 in the same period last year[3]. - Net profit attributable to shareholders was CNY 55,965,884.89, up 20.49% from CNY 46,447,471.21 year-on-year[3]. - The net profit after deducting non-recurring gains and losses was CNY 54,475,155.84, reflecting a 47.21% increase from CNY 37,005,821.13 in the previous year[3]. - Basic and diluted earnings per share increased to CNY 0.24, a 20.00% rise from CNY 0.20 in the previous year[3]. - Total operating revenue for the first quarter was CNY 449,062,914.36, an increase from CNY 278,106,139.44 in the previous year, representing a growth of 61.4%[24]. - Net profit for the first quarter reached CNY 55,965,884.89, compared to CNY 46,447,471.21 in the same period last year, reflecting a year-over-year increase of 20.5%[27]. Cash Flow and Liquidity - The company's cash flow from operating activities showed a net outflow of CNY -1,848,282.70, a decline of 114.22% compared to a net inflow of CNY 13,000,922.98 in the same period last year[3]. - The cash inflow from operating activities totaled approximately ¥501.68 million, a significant increase from ¥298.41 million in the previous period, representing a growth of about 68%[31]. - The cash outflow from operating activities amounted to approximately ¥503.52 million, compared to ¥285.41 million in the prior period, indicating an increase of around 76%[34]. - The net cash flow from operating activities was negative at approximately -¥1.85 million, a decline from a positive ¥13.00 million in the previous period[34]. - Cash inflow from investment activities was approximately ¥160.85 million, while cash outflow was about ¥76.33 million, resulting in a net cash flow from investment activities of approximately ¥84.53 million[34]. - The net increase in cash and cash equivalents was approximately ¥78.65 million, compared to ¥6.95 million in the previous period, reflecting a substantial improvement[34]. - The ending balance of cash and cash equivalents stood at approximately ¥455.05 million, up from ¥138.47 million at the end of the previous period[37]. - The company reported a significant increase in cash received from sales of goods and services, totaling approximately ¥487.45 million, compared to ¥278.44 million previously, marking a growth of about 75%[31]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,769,440,435.14, a 1.39% increase from CNY 1,745,236,782.31 at the end of the previous year[3]. - The total liabilities decreased to CNY 613,765,871.88 from CNY 645,899,203.77, indicating a reduction of approximately 5%[23]. - The total equity attributable to shareholders increased to CNY 1,155,674,563.26 from CNY 1,099,337,578.54, marking a growth of 5.1%[23]. - The total non-current assets decreased slightly to ¥721,047,512.86 from ¥724,964,584.98, showing a decline of about 0.5%[17]. Expenses - The company's R&D expenses rose to CNY 34,289,853.06, an increase of 43.77% compared to CNY 23,849,997.16 in the previous year, indicating a focus on new product development[6]. - The company reported a significant increase in sales expenses, which reached CNY 237,781,400.74, up 79.98% from CNY 132,112,583.11, reflecting enhanced market expansion efforts[6]. - The company's total operating costs were CNY 386,227,834.47, compared to CNY 233,213,680.72 in the previous year, reflecting a rise of 65.7%[24]. - The company experienced a 297.01% increase in financial expenses, amounting to CNY 3,675,983.98, mainly due to increased convertible bond interest[6]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,005, with the largest shareholder, Zhu Zhihong, holding 35.75% of shares, amounting to 83,910,000 shares[10]. - The largest shareholder, Zhu Zhihong, holds 20,977,500 unrestricted shares[10]. - The company has not disclosed any related party relationships among the top ten shareholders[13]. - The company has not reported any changes in restricted shares during the period[14]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[26].

Financial Performance - The company's revenue for Q3 2021 reached ¥397,864,203.25, representing a 50.97% increase compared to the same period last year[3]. - Net profit attributable to shareholders was ¥56,395,038.67, a significant increase of 152.17% year-on-year[3]. - The net profit excluding non-recurring gains and losses was ¥52,771,854.35, up 195.79% from the previous year[3]. - Basic earnings per share increased to ¥0.24, reflecting a growth of 140.00% compared to the same quarter last year[3]. - Total operating revenue for the current period reached ¥1,129,600,415.75, a significant increase from ¥656,824,252.48 in the previous period, representing a growth of approximately 72%[25]. - Net profit for the current period was ¥169,211,746.27, compared to ¥55,186,026.50 in the previous period, reflecting an increase of approximately 206%[28]. - Basic and diluted earnings per share for the current period were both ¥0.72, up from ¥0.24 in the previous period, marking a 200% increase[32]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,640,210,752.51, a 45.06% increase from the end of the previous year[3]. - Total assets reached ¥1,640,210,752.51, compared to ¥1,130,719,874.02 at the end of the previous year, marking a growth of 45%[19]. - Total liabilities increased to ¥576,051,829.19 from ¥295,037,659.68, indicating a rise of about 95%[24]. - Current liabilities increased to ¥286,725,953.00 from ¥180,959,561.14, a rise of 58.5%[20]. - Non-current liabilities decreased from ¥70,502,269.37 to ¥39,656,375.68, a reduction of 43.8%[20]. Cash Flow - Cash flow from financing activities showed a significant increase of 490.56%, totaling ¥283,748,349.99, primarily due to the issuance of convertible bonds[9]. - Cash flow from operating activities amounted to ¥1,228,947,707.34, compared to ¥694,178,138.48 in the previous period, showing an increase of about 77%[33]. - The net cash flow from financing activities was CNY 283,748,349.99, a significant improvement from a net outflow of CNY -72,651,373.62 previously[39]. - The total cash inflow from financing activities amounted to CNY 310,000,000.00, compared to CNY 9,500,000.00 in the previous period[39]. - The total cash outflow from operating activities was CNY 1,172,897,031.10, compared to CNY 629,251,967.53 in the previous period[36]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 12,245[10]. - The largest shareholder, Zhu Zhihong, holds 35.76% of shares, totaling 83,910,000 shares[10]. - The company has a total of 62,932,500 shares with restricted voting rights held by priority shareholders[10]. Research and Development - Research and development expenses rose to ¥90,708,588.17, a 52.02% increase year-on-year, indicating a focus on innovation[9]. - Research and development expenses for the current period totaled ¥90,708,588.17, compared to ¥59,667,670.00 in the previous period, representing a growth of approximately 52%[28]. Inventory and Receivables - Accounts receivable rose to ¥223,210,658.96, up from ¥164,284,293.84, indicating a year-over-year increase of 36%[17]. - Inventory increased to ¥210,486,409.83 from ¥153,117,867.75, reflecting a growth of 37.5%[17]. - The company reported a significant increase in other receivables, which rose to ¥7,779,310.78 from ¥1,025,216.92, a growth of 658%[17].

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 731,736,212.50, representing an increase of 86.05% compared to CNY 393,292,464.63 in the same period last year[27]. - The net profit attributable to shareholders of the listed company reached CNY 112,816,707.60, a significant increase of 243.72% from CNY 32,822,002.07 in the previous year[27]. - The net profit after deducting non-recurring gains and losses was CNY 101,840,900.89, up 272.51% from CNY 27,339,148.19 in the same period last year[27]. - The net cash flow from operating activities was CNY 66,817,618.56, an increase of 32.23% compared to CNY 50,532,296.22 in the previous year[27]. - The basic earnings per share were CNY 0.48, up 242.86% from CNY 0.14 in the same period last year[27]. - The total assets at the end of the reporting period were CNY 1,572,473,978.71, reflecting a growth of 39.07% from CNY 1,130,719,874.02 at the end of the previous year[27]. - The net assets attributable to shareholders of the listed company were CNY 1,007,763,884.65, an increase of 20.59% from CNY 835,682,214.34 at the end of the previous year[27]. - The weighted average return on net assets was 12.67%, an increase of 8.45% compared to 4.22% in the previous year[27]. Business Strategy and Development - The company aims to focus on new business development, product research, marketing reform, and capacity construction to enhance management efficiency and brand image[42]. - The company has successfully completed its semi-annual operational goals, setting a strong foundation for its three-year strategic plan[42]. - The increase in revenue and net profit is primarily due to the low base from the previous year affected by the pandemic and the gradual realization of market expansion efforts[45]. - The company is actively pursuing new product development across various therapeutic areas, including anti-allergy and anti-hypertensive medications[45]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[56]. - The company is expanding its market presence with a focus on chronic diseases and gastrointestinal treatments[48]. - The company is committed to enhancing its product offerings through continuous innovation and strategic evaluations[48]. Research and Development - As of the end of the reporting period, the company and its subsidiaries had 86 ongoing research projects[45]. - Key projects in clinical research include Indomethacin Gel and Hydrochloride Acarbose Tablets, both aimed at pain relief and digestive system treatments[45]. - The company has ongoing patent applications for new formulations, such as Pantoprazole sodium enteric-coated tablets[51]. - The company has a research and development team of over 400 members, primarily composed of PhDs, Masters, and overseas returnees, demonstrating strong R&D capabilities[67]. - The company has made significant investments in research and development, as evidenced by the increase in patents and copyrights[78][81]. Market and Industry Trends - The overall trend in the pharmaceutical industry remains positive, with expectations for continued growth driven by healthcare reforms and increasing public health awareness[39]. - The pharmaceutical manufacturing industry achieved a revenue of CNY 24,857.3 billion in 2020, with a year-on-year growth of 4.5%[40]. - In the first five months of 2021, the pharmaceutical manufacturing sector realized a revenue of CNY 11,162.3 billion, reflecting a year-on-year increase of 27.6%[40]. - The profit margin for the pharmaceutical manufacturing industry was approximately 14.1% in 2020, which improved by 1.1 percentage points compared to the previous year[40]. Environmental Compliance and Social Responsibility - The company has established an environmental self-monitoring plan in accordance with its pollution discharge permit, which is regularly monitored by a qualified third-party agency[166]. - The company actively engages in social responsibility initiatives, including creating employment opportunities and supporting local economic development[170]. - The company has implemented a performance evaluation system for employee management, ensuring compliance with labor laws and providing various employee benefits[167]. - The company has established emergency response measures, including a micro fire station equipped with necessary rescue materials[161]. Risks and Challenges - The company has faced risks and has outlined corresponding measures in the report[6]. - The company acknowledges the risk of rising accounts receivable due to business growth, which may lead to bad debt risks[124]. - The company is exposed to risks from centralized drug procurement policies, which could adversely affect sales if products do not win bids or if bid prices drop significantly[122]. - Environmental protection risks are present due to the nature of the pharmaceutical industry, with potential penalties for non-compliance with environmental standards[127]. Corporate Governance - The company did not distribute cash dividends or bonus shares for the first half of 2021[136]. - The company has not engaged in any related party transactions during the reporting period, ensuring transparency and compliance with governance standards[181]. - The company has not undergone any asset or equity acquisitions or sales during the reporting period, maintaining its current operational structure[182].

Financial Performance - The company's revenue for Q1 2021 was ¥278,106,139.44, representing a 73.31% increase compared to ¥160,465,601.52 in the same period last year[9]. - Net profit attributable to shareholders reached ¥46,447,471.21, a significant increase of 553.18% from ¥7,110,935.41 in the previous year[9]. - The net profit after deducting non-recurring gains and losses was ¥37,008,478.80, up 602.59% from ¥5,267,419.58 year-on-year[9]. - Basic earnings per share increased to ¥0.20, reflecting a growth of 566.67% compared to ¥0.03 in the same period last year[9]. - Total operating revenue for Q1 2021 reached ¥278,106,139.44, a significant increase from ¥160,465,601.52 in the same period last year, representing a growth of approximately 73.4%[74]. - The company's total profit for the current period was ¥54,462,950.90, compared to ¥7,274,839.99 in the previous period, an increase of 648.0%[80]. - The company reported other income of ¥10,235,579.41, significantly higher than ¥2,369,352.20 in the previous period, an increase of 331.5%[80]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,214,152,832.99, a 7.38% increase from ¥1,130,719,874.02 at the end of the previous year[9]. - The company's total assets as of March 31, 2021, amounted to ¥1,068,924,382.18, compared to ¥1,010,169,893.59 at the end of 2020, indicating an increase of about 5.8%[72]. - The total liabilities increased to ¥144,601,964.50 from ¥138,278,904.69, reflecting a rise of approximately 4.7%[72]. - The equity attributable to shareholders of the parent company rose to ¥924,322,417.68, up from ¥871,890,988.90, marking an increase of around 6.0%[72]. - The company's cash and cash equivalents increased to CNY 145.12 million from CNY 135.26 million, reflecting improved liquidity[56]. - Cash and cash equivalents at the end of the period reached 138,466,537.36, compared to 115,159,925.13 at the end of the previous period, marking an increase of approximately 20.2%[98]. Cash Flow - The net cash flow from operating activities was ¥13,000,922.98, a decrease of 15.81% from ¥15,442,989.83 in the same period last year[9]. - Cash inflow from operating activities totaled 298,414,653.06, compared to 184,542,238.28 in the previous period, reflecting a growth of approximately 61.6%[96]. - Cash received from sales of goods and services was 278,435,959.74, up from 177,197,979.34, indicating a year-over-year increase of about 57.1%[92]. - Cash inflow from financing activities was 20,000,000.00, up from 9,500,000.00, representing a growth of 110.5%[98]. - Cash outflow from financing activities decreased to 2,697,620.21 from 17,600,155.73, showing a reduction of about 84.7%[98]. Research and Development - Research and development expenses increased by 59.49% to CNY 23.85 million, reflecting higher spending on R&D projects[23]. - The company has several ongoing R&D projects, including indomethacin gel and hydrochloride acotiamide tablets, currently in clinical research stages[27]. - JiuDian Pharmaceutical has multiple R&D projects in progress, including 10 projects focused on anti-inflammatory and analgesic drugs, with all in the preclinical research stage[19]. - The company has a total of 17 drug development projects in the pre-registration research phase, focusing on various therapeutic areas including anti-inflammatory and analgesic drugs[34]. - The company emphasizes the importance of product and technology development as a core competitive advantage, with a focus on risk control in the R&D process[38]. Market Strategy and Compliance - The company is committed to enhancing its market presence through the development of innovative products and potential market expansions[32]. - The implementation of the "Two Invoice System" has led to an increase in the proportion of sales through cooperative distribution models, enhancing market reach[44]. - Environmental compliance remains a focus, with the company implementing a high-standard EHS management system to mitigate potential regulatory risks[46]. - The company is addressing potential risks related to intellectual property protection and market competition through systematic management and legal compliance[39]. - The company is diversifying its product line to mitigate the impact of antibiotic regulation on revenue growth[40]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,633[12]. - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[68].